Gabriel Holding A/S (CPH:GABR) on Thursday reported profit before tax of DKK14.2m for the first quarter of the financial year 2017/18 .
This was a 49% increase as compared with profit before tax of DKK9.5m in Q1 2016/17.
Operating profit (EBIT) for the quarter increased by 64% to DKK13.7m, as compared with DKK8.4m in Q1 2016/17.
Revenues for the quarter increased by 24% to DKK144.7m, as compared with DKK117.0m in Q1 2016/17. Reportedly, this increase in revenues is a result of growth on the main markets and in all business units.
The company provided expectations for the 2017/18 financial year and expects growth in revenues and earnings for the full year to get close to 15% in the range of 10% to 15% stated in the annual report. This is as a result of revenues and earnings realised for the quarter exceed management's expectations.
Gabriel Holding develops, manufactures, and sells furniture fabrics of pure wool and micro fibres, and related textile products. The company's product line includes fabrics for upholstered furniture, as well as for office, theatre, hospital, and hotel furniture, as well as furnishing fabrics for trains, ships, cars and buses.
(EUR1.00=DKK7.44)
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation